Protagenic Therapeutics Inc. (PTIX) - Long-Term Liabilities to Capital

Protagenic Therapeutics (PTIX) generates revenue through the commercialization of neurotherapy treatments, specifically anti-anxiety and antidepressant drugs, as illustrated by the price chart with the 0.00 indicator. As part of its ESG strategy, the firm is optimizing energy consumption and air purification within its laboratories. Meanwhile, a cohesive management team ensures a stable growth trajectory by adhering to prudent capital management and flexible planning for clinical trials.

Protagenic Therapeutics (PTIX) focuses on high-tech neurobiology developments to combat depression. By analyzing the long-term debt-to-equity ratio, we assess the proportion of loans with maturities exceeding one year relative to shareholders' equity. A low level of this metric indicates minimal financial pressure on the company. Such a balance sheet structure confirms the brand's resilience during prolonged clinical trials. Conservative leverage provides robust investment protection amid market volatility.